O
Oscar Calaforra
Researcher at Carlos III Health Institute
Publications - 5
Citations - 86
Oscar Calaforra is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Pulse wave velocity & Outpatient clinic. The author has an hindex of 5, co-authored 5 publications receiving 68 citations. Previous affiliations of Oscar Calaforra include University of Valencia.
Papers
More filters
Journal ArticleDOI
Pulse pressure amplification and its determinants
TL;DR: Gender, age and body composition have a significant impact on PP amplification, and PP amplification is related to BP: the higher the BP, the lower the PP amplification.
Journal ArticleDOI
Influence of obesity in central blood pressure.
G. Pichler,Fernando Martinez,Antonio Vicente,E. Solaz,Oscar Calaforra,Empar Lurbe,Josep Redon +6 more
TL;DR: Overweight and obesity tend to have lower central blood pressure as compared to lean patients, mainly in women, and PWV was lower in the overweight/obese group compared to the normal-weight group at the same central SBP.
Journal ArticleDOI
Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease.
G. Pichler,Josep Redon,Fernando Martinez,E. Solaz,Oscar Calaforra,Marta San Andres,Begoña López,Javier Díez,Rainer Oberbauer,Christopher Adlbrecht,Georg Delle Karth,Alicia M. Maceira +11 more
TL;DR: In individuals with HHD, CMR-derived measures of myocardial fibrosis and function are related and might be useful tools for the identification and characterization of preclinical cardiac dysfunction and diffuse myocardia fibrosis.
Journal ArticleDOI
Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: A multicenter, randomized, double-blind study
Josep Redon,Jose Mª Pascual-Izuel,Enrique Rodilla,Antonio Vicente,Josefina Oliván,Josep Bonet,Josep Pere Torguet,Oscar Calaforra,Jaume Almirall +8 more
TL;DR: The study confirms that nebivolol produces a less pronounced impact on augmentation index than atenolol, and modified the mean augmentation Index to a lesser extent than atanolol after 10 weeks.
Journal ArticleDOI
Carotid-femoral pulse wave velocity assessment by two different methods: implications for risk assessment.
TL;DR: The concordance between the Complior and the SphygmoCor device is poor when the anatomical artery length is controlled for and in the presence of cardiovascular risk factors, resulting in a difference in classification of cardiovascularrisk.